Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 14;11(4):994.
doi: 10.3390/jcm11040994.

Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases

Anna Kofla-Dłubacz  1 , Katarzyna Akutko  1 , Elżbieta Krzesiek  1 , Tatiana Jamer  1 , Joanna Braksator  1 , Paula Grębska  1 , Tomasz Pytrus  1 , Andrzej Stawarski  1
Affiliations
Review

Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases

Anna Kofla-Dłubacz et al. J Clin Med. .

Abstract

Selective interference with the functioning of the immune system consisting of the selective blockade of pro-inflammatory factors is a modern, promising, and developing strategy for the treatment of diseases resulting from dysregulation of the immune system, including inflammatory bowel disease. Inhibition of the TNF alpha pathway, group 12/23 cytokines, and lymphocyte migration is used in the treatment of severe or moderate ulcerative colitis and Crohn's disease. Intracellular signal transduction by influencing the phosphorylation of SAT (signal transducer and activator of transcription) proteins remains in clinical trials.

Keywords: IBD; lymphocyte migration; pro-inflammatory cytokines; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Yan J., Smyth M.J., Teng M.W.L. Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Cold Spring Harb. Persp. Biol. 2018;10:a028530. doi: 10.1101/cshperspect.a028530. - DOI - PMC - PubMed
    1. Idriss H.T., Naismith J.H. TNF alpha and the TNF receptor superfamily: Structure-function relationship(s) Microsc. Res. Tech. 2000;50:184–195. doi: 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H. - DOI - PubMed
    1. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 2008;117:244–279. doi: 10.1016/j.pharmthera.2007.10.001. - DOI - PubMed
    1. Billmeier U., Dieterich W., Neurath M.F., Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J. Gastroenterol. 2016;22:9300–9313. doi: 10.3748/wjg.v22.i42.9300. - DOI - PMC - PubMed
    1. Remicade SoPC. [(accessed on 4 February 2022)]. Available online: https://ec.europa.eu/health/documents/community-register/2004/2004092082....